» Articles » PMID: 31973537

MicroRNA-506-3p Inhibits Proliferation and Promotes Apoptosis in Ovarian Cancer Cell Via Targeting SIRT1/AKT/FOXO3a Signaling Pathway

Overview
Journal Neoplasma
Specialty Oncology
Date 2020 Jan 25
PMID 31973537
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer (OC) is one of the most common tumors in females. Growing evidence shows that microRNA-506-3p (miR-506-3p) is downregulated in OC tissues. The purpose of this study was to investigate the mechanism of miR-506-3p in modulating OC. Quantitative reverse transcriptase PCR (qRT-PCR) was employed to investigate the expression of miR-506-3p and its target in OC tissues or cell lines. CCK-8 or colony formation assay was used to examine cell viability or proliferation, respectively. Flow cytometry was demonstrated to detect cell apoptosis. Western blot was then applied to analyze underlying mechanisms. The potential target of miR-506-3p was examined via luciferase reporter assay. MiR-506-3p was significantly downregulated in both human OC tissues and cell lines. Overexpression of miR-506-3p not only decreased cell viability of OC cell lines but also promoted cell apoptosis, thus inhibiting OC progression. Moreover, SIRT1 (Sirtuin 1) was found to be a direct target of miR-506-3p, and SIRT1 expression was negatively regulated by miR-506-3p in OC cell lines. Further investigation revealed that overexpression of SIRT1 could promote cell viability as well as inhibit cell apoptosis, showing the reversed effect on OC progression compared to miR-506-3p. Lastly, AKT (Protein kinase B) /FOXO3a (Forkhead box O3) signaling pathway was inactivated by miR-506-3p while activated by SIRT1, relating to regulation of miR-506-3p on OC progression. Our results revealed a novel mechanism by which miR-506-3p inhibited proliferation while promoted apoptosis of OC via inactivation of SIRT1/AKT/FOXO3a signaling pathway, suggesting that miR-506-3p might be a potential target for OC.

Citing Articles

FOXO3a deregulation in uterine smooth muscle tumors.

de Almeida T, Ricci A, Dos Anjos L, Soares Junior J, Maciel G, Baracat E Clinics (Sao Paulo). 2024; 79:100350.

PMID: 38636197 PMC: 11031728. DOI: 10.1016/j.clinsp.2024.100350.


FOXO3a-interacting proteins' involvement in cancer: a review.

Dong Z, Guo Z, Li H, Han D, Xie W, Cui S Mol Biol Rep. 2024; 51(1):196.

PMID: 38270719 DOI: 10.1007/s11033-023-09121-w.


MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis.

Taghehchian N, Lotfi M, Zangouei A, Akhlaghipour I, Moghbeli M Eur J Med Res. 2023; 28(1):330.

PMID: 37689738 PMC: 10492305. DOI: 10.1186/s40001-023-01329-7.


A plasma 3-marker microRNA biosignature distinguishes spinal tuberculosis from other spinal destructive diseases and pulmonary tuberculosis.

Liang Q, Jin W, Huang Z, Yin H, Liu S, Liu L Front Cell Infect Microbiol. 2023; 13:1125946.

PMID: 36926516 PMC: 10011472. DOI: 10.3389/fcimb.2023.1125946.


[Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].

Zhang P, He M, Zeng Y, Cai X Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(1):8-16.

PMID: 36856205 PMC: 9978720. DOI: 10.12122/j.issn.1673-4254.2023.01.02.